Transaction Details and Timeline
The definitive business combination agreement sets an implied equity valuation of approximately $1.5 billion for PrimeGen US. The closing remains contingent on:
-
Stockholder approval from both PrimeGen US and DT Cloud Star
-
Receipt of regulatory approvals
-
Satisfaction of minimum cash conditions
-
Other customary closing requirements outlined in the agreement
Upon closing, the combined company is expected to operate as PrimeGen US under a new Nasdaq ticker symbol, subject to exchange approval.
Although the transaction is projected to close in the second half of 2026, the companies cautioned that timing and completion are not guaranteed.
A Step Toward Growth
The deal positions PrimeGen US to accelerate its clinical programs, expand development capabilities, and potentially bring breakthrough therapies to patients more quickly. The SPAC route offers the firm a fast-track entry into public markets, combining capital infusion with market visibility to fuel its next stage of growth.
